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It is believed that androgens and their receptors regulate normal prostate growth and mediate prostate
cancer development. Androgen deprivation therapy is the most commonly used treatment for advanced
prostate cancer. Although the therapy is initially effective, progression of the disease to castration-
resistant prostate cancer is almost inevitable, leading to treatment failure. Despite the existence of
current clinical parameters, new biomarkers are urgently needed to improve the prognosis. Some
molecules and DNA-based genetic biomarkers are under investigation as potential prognostic factors.
The advancement in molecular cytogenetic research, such as genome-wide association for single-
nucleotide polymorphisms, has made possible the detection of genetic mutations. In this study, a liter-
ature search from August 1985 to April 2013 was performed through the PubMed database using the
keywords “genetic polymorphisms”, “prostate cancer” and “androgen deprivation therapy”. The results
revealed that several genome-wide association studies (such as rs16901979, rs7931342, HSD17B4, rs6162
in the CYP17A1, rs4243229 and rs7201637 in the HSD17B2, rs1062577 in the ESR1, SLCO1B3, SLCO2B1,
rs2939244 in the ARRDC3, rs9508016 in the FLT1, rs6504145 in the SKAP1, rs7830611 in the FBXO32,
rs9508016 in the FLT1, rs12529 in the AKR1C3, rs16934641 in the BNC2, rs3763763 in the TACC2,
rs2051778 in the ALPK1, and rs3763763 in the TACC2, AR, ESR1, and ESR2) and single-nucleotide poly-
morphisms in important pathways (such as androgen signal, biosynthesis, metabolism, androgen re-
ceptor binding site, response element, androgen receptor CAG repeat polymorphism length, and estrogen
receptor-binding sites) involved in prostate cancer occurrence and mechanism could serve as candidate
biomarkers for the early detection of castration-resistant prostate cancer after androgen deprivation
therapy. Additional investigations are required to decipher precisely the gene combinations and
personalize the management of prostate cancer.
Copyright © 2014, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
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Due to the early screening of prostate speciﬁc antigen (PSA)
levels, prostate cancer can be detected at the beginning of its pro-
gression. However, 10e20% of newly diagnosed prostate cancer
patients are already in the advanced disease stages.1,2 It is widely
accepted that androgen deprivation therapy (ADT) is one of the
treatment choices for advanced prostate cancer. ADT can progressan LLC. Open access under CC BY-NC-ND license.
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pectancy of the patient may become only 16e18months.2 There are
some clinical prognostic factors, such as tumor stage, Gleason score,
and PSA kinetics, for the presentation of the disease; however, a
proper surrogate for predicting survival remains unknown. The
clinical stage incorporation of genetic markers has been proposed
by some investigators. Previous studies3e13 have shown that
germline genetic variants have the potential to identify predispo-
sition to aggressive prostate cancer. This complex disease still needs
further elucidation of the biological pathways involved in its initi-
ation and progression.
The purpose of this mini-review article was to investigate pre-
vious reports regarding the prognostic signiﬁcance of genetic
polymorphisms on disease progression and survival after ADT.
2. Materials and methods
The PubMed database was searched from August 1985 to April
2013 for related articles using the keywords “genetic poly-
morphisms”, “prostate cancer” and “androgen deprivation ther-
apy”. Only articles in English and including human participants
were included in the current literature review. The articles related
to the keywords genetic polymorphism, androgen deprivation
therapy, and prostate cancer were additionally collected in this
study. In total, 21 articles were identiﬁed and included in this mini-
review.
3. Results and discussion
3.1. Prostate cancer susceptibility variants
The risk of prostate cancer has recently been identiﬁed by
several genome-wide association studies (GWASs). However, Asian
male patients receiving ADT have not been evaluated for the risk
variants in advanced prostate cancer. Bao et al4 analyzed 19 pros-
tate cancer susceptibility variants as prognostic predictors for sur-
vival after ADT. Their study cohort collected 601 prostate cancer
patients treated with ADT. Prostate cancer-speciﬁc mortality
(PCSM) and all-cause mortality (ACM) after ADT were assessed by
KaplaneMeier analysis and Cox's regression model. Two poly-
morphisms, rs16901979 and rs7931342, were signiﬁcantly associ-
ated with PCSM (p ¼ 0.005 for rs16901979 and p ¼ 0.038 for
rs7931342), and rs16901979 was also associated with ACM
(p ¼ 0.003) following ADT. It has been reported that the effect of
rs7931342 is inﬂuenced by other known clinical factors and that
rs16901979 remains a signiﬁcant predictor for PCSM and ACM after
ADT (p¼ 0.002). Furthermore, the risk evaluation of PCSM and ACM
in high-risk patients with distant metastasis (p < 0.017) can be
increased by combination of rs16901979 status and the current
clinical staging system.
3.2. Genetic polymorphism in androgen signaling, biosynthesis, and
metabolic pathway
It is believed that the development of normal prostate and
prostate cancer is highly associated with androgen levels. There-
fore, the androgen receptor (AR), a nuclear receptor superfamily,
plays a critical role inmediating the biological effects of androgen.14
Gene expression mediated by the promoter region of androgen-
responsive genes in target tissues14 is regulated by the andro-
geneAR complex that interacts with co-regulators and binds to
speciﬁc androgen-responsive elements (AREs). In a study by Ross
et al,5 a cohort of 529 advanced prostate cancer patients treated
with ADT were genotyped for 129 DNA polymorphisms distributed
across 20 genes involved in androgen metabolism. The authorshypothesized that the efﬁcacy of ADT could be improved by
germline genetic variations in the androgen axis. Three poly-
morphisms in separate genes (CYP19A1, HSD3B1, and HSD17B4)
were considered signiﬁcant (p < 0.01) by multivariate analyses
associated with time to progression (TTP) during ADT. Patients with
more than one polymorphism were associated with improved TTP
and a better response to therapy (p < 0.0001). The pharmacoge-
nomics on an individual's response to ADT were inﬂuenced by an
inherited variation of the androgen metabolic pathway. Two
separate cohorts were examined by Levesque et al.6 They enrolled
526 Caucasian men with organ-conﬁned prostate cancer and 601
Taiwanese men on ADT. There were 109 haplotype-tagging single-
nucleotide polymorphisms (SNPs) in CYP17A1, ESR1, CYP19A1, and
HSD3B1 tested in Caucasians. KaplaneMeier survival curves and
Cox's regression models were used for the prognostic signiﬁcance
on disease progression. Then, the authors tested their ﬁndings,
including the previous positive ones, in Taiwanese men (n ¼ 32
SNPs). They used speciﬁc and sensitive mass-spectrometry-based
methods to evaluate the inﬂuence of these markers on the circu-
lating hormonal levels. In both cohorts, variants of CYP17A1
(rs6162), HSD17B2 (rs4243229 and rs7201637), and ESR1
(rs1062577) were related to disease progression. These variations
were highly related to the progression of the disease in Caucasians
(hazard ratio: 2.29e4.10; p ¼ 0.0014e2  107) and survival rate in
Taiwanese populations (hazard ratio ¼ 3.74; 95% conﬁdence
interval ¼ 1.71e8.19, p ¼ 0.009). Plasma dehydroepiandrosterone
sulfate levels were inﬂuenced by the CYP17A1 rs6162 poly-
morphism (p ¼ 0.03), dihydrotestosterone by the HSD17B2
rs7201637 (p ¼ 0.03), and estrone-S and androsteroneeglucur-
onide by the ESR1 rs1062577 (p  0.05). This study showed that
CYP17A1, HSD17B2, and ESR1 could be candidate prognostic factors
for prostate cancer progression in different ethnic groups and even
in different disease stages.
3.3. SLCO2B1 and SLCO1B3
Wright et al7 studied the efﬁcacy of ADT in prostate cancer
patients through genetic variation in SLCO1B3 and SLCO2B1. The
genetic variation of SLCO genes maymodify androgen uptake. They
found that the genetic variation between castration-resistant
prostate cancer (CRPC) metastases patients and primary prostate
cancer patients are associated with high SLCO1B3 and SLCO2B1
expression. The overexpression of these variants was also associ-
ated with the elevated risk of PCSM. Yang et al8 investigated ge-
notype SLCO2B1 and SLCO1B3 SNPs in a cohort of 538 patients with
prostate cancer treated with ADT. They found that TTP on ADT was
highly related to three SNPs in SLCO2B1 (p < 0.05). It took 10
months to reveal the differences in median TTP for each of these
polymorphisms. The SLCO2B1 genotype plays a vital role in
enhancing the efﬁcient import of androgen, thus accelerating cell
growth, which is associated with a shorter TTP on ADT. A median
2-year shorter TTP on ADT was noted for patients carrying both
SLCO2B1 and SLCO1B3 genotypes. The capability for transporting
dehydroepiandrosterone sulfate into the cells was increased in
SLCO2B1-312Arg-variant LNCaP cells.
3.4. AR binding site
Recent studies have shown that prostate tumor progression is
mediated by AR binding to AREs in the genome.2,3,14 Huang et al9
studied the relationship between the genetic variants in AREs and
the clinical outcomes after ADT in prostate cancer patients. They
included 601 prostate cancer patients treated with ADT. Fifty-ﬁve
SNPs were investigated in the genome-wide in silico-predicted
AREs. After adjusting for several known prognostic factors, ARRDC3
T.-Y. Huang et al. / Urological Science 26 (2015) 81e84 83rs2939244, FLT1 rs9508016, and SKAP1 rs6504145 were still sig-
niﬁcant predictors for PCSM, and FBXO32, rs7830622, and FLT1
rs9508016 remained signiﬁcant predictors for ACM in multivariate
analysis. Furthermore, there were strong combined genotype
effects on PCSM and ACM (p < 0.001).
3.5. G/A polymorphism in the ARE1 of the PSA gene
PSA gene expression is regulated by AR through AREs present in
the promoter region of the gene.15,16 The substitution of G to A at
position 158 in ARE of the PSA gene has been speculated in some
reports.17 Shibahara et al10 showed no difference in the promoter
activity and binding capacity of the AR in vitro between the two
alleles in the Japanese population. Polymerase chain reaction
ampliﬁcation and restriction digestion assays were performed in
101 patients who underwent radical prostatectomy, thus showing
PSAe158 G/A polymorphism. The homozygosity for the A allele is
less common in the Japanese population than that in other ethnic
populations. The serum PSA level did not show any differences in
the differentiation of cancer, pathological stages, cancer volume, or
ratio of serum PSA/cancer volume at the time of diagnosis. It is
notable that after neoadjuvant endocrine therapy, cancer volume
was signiﬁcantly smaller in the GG genotype than that in the
AA þ AG genotype. Therefore, their study showed no effect on the
PSA promoter activity in vitro and no association with the serum
PSA level in the PSAe158 G/A polymorphism in Japanese men.
However, the patients with the GG genotype of ARE1 may be more
sensitive to androgen ablation therapy.
3.6. AR CAG repeat polymorphism length
ADT has shown the ability to suppress androgen production or
AR activity. However, aggressive CRPC is often observed after ADT.18
Several possible mechanisms were proposed to explain the devel-
opment of CRPC.18,19 Low androgen levels can also activate AR re-
sponses by the alteration of transcriptional coactivators and
activation of signaling pathways. There were no signiﬁcant differ-
ences in intraprostatic androgens between castrated men with
CRPC and that of menwith a normal prostate. The cancer cells may
produce intracellular hormones to promote their own growth.
Therefore, many studies focus on the sex hormone metabolic
pathways and genetic variants as predictive factors. Yu et al11
investigated whether the host genetic variations in sex hormone
pathway genes are associated with the efﬁcacy of ADT. There were
18 polymorphisms across 12 key genes involved in androgen and
estrogen metabolism included in a cohort of 645 patients with
advanced prostate cancer treated with ADT. The results showed
that AKR1C3 rs12529 and AR CAG repeat length remained signiﬁ-
cantly associated with PCSM after ADT (p  0.041). In addition, a
13.7-fold increased risk of PCSM was found in individuals carrying
two unfavorable genotypes at these loci than those carrying no
unfavorable genotypes (p < 0.001). Two candidate molecular
markers in the key genes of androgen and estrogen pathways
associated with PCSM after ADT were identiﬁed to establish the
role of pharmacogenomics in this therapy.
3.7. Genetic polymorphisms in estrogen receptor binding sites
versus inherited variation of the AR, ESR1, and ESR2 genes
Recent reports have demonstrated that estrogen and its corre-
sponding receptor are correlatedwith prostate cancer development
and progression.20,21 The main biological effects are mediated by
the binding to estrogen response elements (EREs) in the regulatory
regions of the target genes.21 The variety of sequences in EREs
might be associated with estrogen receptoreERE physiologicalactivities. Huang et al12 used a genome-wide database in a cohort of
601 men with advanced prostate cancer treated with ADT by
evaluating 49 ERE SNPs. The result showed that BNC2 rs16934641
was highly associated with disease progression; furthermore,
TACC2 rs3763763 was correlated with PCSM, and ALPK1 rs2051778
and TACC2 rs3763763 were correlated with ACM. In multivariate
analysis, these SNPs remained signiﬁcant because they included
known clinical pathological predictors. Moreover, the combination
of the genomic effect was observed on ACMwhen ALPK1 rs2051778
and TACC2 rs3763763 were both present. Patients who had more
unfavorable genotypes had a shorter time to ACM during ADT
(p < 0.001). Therefore, ERE SNPs may correlate with known pre-
dictors and improve the outcome prediction in patients with
prostate cancer receiving ADT.
By contrast, commonly inherited variation in the AR, ESR1, and
ESR2 genes, studied by Sun et al13 to investigate the risk of devel-
oping aggressive prostate cancer and the response to ADT in a
hospital-based cohort, showed different results. There were 43
tagging SNPs covering the loci of AR (n ¼ 4), ESR1 (n ¼ 32), and
ESR2 (n ¼ 7) successfully genotyped in 4073 prostate cancer pa-
tients. None of these SNPs were correlated with disease severity by
evaluating the D'Amico risk classiﬁcation, pathological stage, or the
response to ADT. The study revealed no statistical difference be-
tween common genetic variations in AR, ESR1 or ESR2 and prostate
cancer severity or response to ADT.
4. Conclusion
The discovery of genetic variants from several genome-wide
association studies and of SNPs involved in the critical pathways
of prostate cancer occurrence and mechanism could serve to
identify candidate biomarkers for the early detection of the pro-
gression of the disease to CRPC after ADT. Clinical implications from
these studies may play a critical role in predicting the responses to
ADT. Additional investigations are required to decipher precisely
the gene combinations and personalize the management of pros-
tate cancer.
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